Recombinant Antibodies, Immunoassay, Tumour Markers: A Review

This report delves into the significance of recombinant antibodies, focusing on their production through gene recombination and their application in the medical and research fields. It highlights the importance of single-chain variable fragments (scFv) in immunoassay, particularly in targeting tumour markers for cancer diagnosis. The report also examines the role of tumour markers, which are substances produced in the body in response to cancer, and how they are used in conjunction with other techniques for cancer detection. Furthermore, the report addresses substrate selection in immunoassay development, emphasizing its crucial role in blocking, stabilization, and detection processes, which directly impacts the sensitivity, specificity, and overall performance of immunoassays. The selection of substrates affects kinetics, dynamic ranges, and timing, all of which are essential for producing reliable results.

Recombinant antibodies
Recombinant antibodies refer to fragments which are produced through the recombination of
coding genes (Kunert & Reinhart, 2016). They majorly entail light and heavy chains of the
immunoglobulin variable region. They play crucial roles in the medical and research arena which are
essential in making active sites for target medication. The common form is a single chain variable
fragment which is often exploited in human medicine. The monoclonal antibodies entail the loss of
the desired capacity to produce antibody over time, making the antibody to undergo unwanted
changes affecting the overall functionality, recombinant ability in the production of the phage display
and maintenance of low and high specificity in the immunogenicity action (Zhong et al., 2015).
Recombinant antibodies offer a wide spectrum of functions ranging from diagnosis to
treatment management therapies for many diagnoses. Their key advantage of having low and high
specificity makes them an alternative form of treatment thus leading to the low occurrence of adverse
effects on patients. The key role in the field of immunoassay towards tumor markers entails the usage
of single chain variable fragment usage. The single chain variable –scFV informs the specificity on
the part of the target modules which target the immune response of specific cancer cells indicating
the target gene (Yuan et al., 2014).
Tumour markers entail substances in the body which are produced in large quantities in
presence of cancer conditions. They are majorly found in blood, stool, and urine or tumoir tissues.
The nature of these substance are protein and are often expressed in gene make up as part of DNA
change which act as tumour markers. Tumours markers are used in collaboration with other
techniques to detect cancer. Tumour markers have provided beneficial assessment and diagnosis of
cancer with the development of calorimeter immunoassays, they have led to much attention due to
high efficiently and simple nature. Many other immunoassay have been developed using the tumour
markers for the diagnosis of cancer (Yin, Cao, Xu & Li, 2010). Other immune essays produced entail
Chomorganin A ELISA, Melatonin Elisa, Serotonin ELISA among others.
Substrate Selection in Immunoassay development
Substrate selection in the overall antigen system is essential in blocking and stabilization
process and the overall detection of the substrates is essential in ensuring the production of robust
results. The key fundamental areas considered for substrate selection entail kinetics, stop reagent,
dynamic ranges and timing essays.
Substrates selection affects the sensitivity and specificity limit performance on the target
sites. Essay having high sensitivity does not offer a lower level of detection which is an important
aspect in the choice of substrates design. Process efficiently and timing is essential in substrates
design as they offer quick development in plates processing, (Acker & Auld, 2014).

References
Acker, M. G., & Auld, D. S. (2014). Considerations for the design and reporting of enzyme assays in
high-throughput screening applications. Perspectives in Science, 1(1-6), 56-73.
Kunert, R., & Reinhart, D. (2016). Advances in recombinant antibody manufacturing. Applied
microbiology and biotechnology, 100(8), 3451-3461.
Yin, Y., Cao, Y., Xu, Y., & Li, G. (2010). Colorimetric immunoassay for detection of tumor
markers. International journal of molecular sciences, 11(12), 5077-5094.
Yuan, R., Chen, X., Chen, Y., Gu, T., Xi, H., Duan, Y., ... & Wu, C. (2014). Preparation and
diagnostic use of a novel recombinant single-chain antibody against rabies virus glycoprotein.
Applied microbiology and biotechnology, 98(4), 1547-1555.
Zhong, N., Loppnau, P., Seitova, A., Ravichandran, M., Fenner, M., Jain, H., ... & Olszewski, M.
(2015). Optimizing production of antigens and Fabs in the context of generating recombinant
antibodies to human proteins. PloS one, 10(10), e0139695.